Navigation Links
Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity
Date:3/10/2008

gy (i.e. screening of potential candidate compounds for toxicity and efficacy using various cancer cell cultures) has suggested would respond better to the agent.

ANAVEX 7-1037 has been previously reported to exhibit high affinity for sigma-1 (nanomolar) receptors and moderate (micromolar) affinity for sigma-2 receptors and sodium channels. In addition, ANAVEX 7-1037 has been shown to induce selective apoptosis (programmed cell death) in HCT116 colon cancer cells in vitro, as detailed in a press release dated December 11, 2007.

These features of ANAVEX 7-1037 have made it one of the company's lead compounds in its efforts to develop pioneering, new anti-cancer drugs for the treatment of solid tumors. ANAVEX 7-1037 has so far been tested in vitro against more than 20 human cancer cell lines representing different types of cancer - it has demonstrated significant in vitro tumor-growth-delaying activity against most of them, as represented by the GI50 (i.e. 50% of the dose required for tumor growth inhibition) of the compound. As such, ANAVEX 7-1037 has been advanced for testing against additional xenografts in order to further establish and confirm its potential as a potent anti-cancer drug.

ANAVEX 7-1037 is being studied for activity against a rare type of melanoma called clear cell sarcoma. Tests are performed by ANAVEX on xenografts developed directly from a sample that was surgically removed from a patient (primary/patient-derived xenografts) suffering from the disease. The patient had been treated with Dacarbazine. This study was implemented as a first step in ANAVEX's efforts to test the activity of the compound against melanoma, as the in-vitro results suggested that the compound may be selective against certain cancer types (such as melanoma, colon, breast and prostate).

Drugs that act on the underlying cause of the disease and/or slow/reverse the progression of the disease, which have a novel mode of action that could fulfill some
'/>"/>

SOURCE Anavex Life Sciences Corp.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Anavex strengthens Board of Directors
2. Anavex advances drug candidate for treatment of Alzheimers disease
3. New Dual Cold Probe From Varian, Inc. Increases Sensitivity and Reduces Analysis Times for 13C NMR Experiments
4. Drug Reduces Airway Mucus in Preclinical Asthma Model
5. Heavier hydrogen on the atomic scale reduces friction
6. ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclinical Tests
7. New Phase III Data Demonstrate Oxycodone / Naloxone Combination Tablet Reduces Opioid-Induced Bowel Dysfunction in Patients With Chronic Severe Pain
8. Landfill mining reduces environmental impact of growing waste
9. Landfill mining reduces environmental impact of growing waste
10. First-Ever Cancer and Careers Seminar Debuts in Orange County
11. Assembly technique for tiny wires may eventually help detect cancer and other diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... (PRWEB) June 19, 2013 Bayer CropScience ... first Bayer Bee Care Community Leadership Award. The award ... Congressional Reception in Washington, D.C., an event where ... to the world’s food supply. , The Bayer ... harnessed the power of the honey bee colony to ...
(Date:6/19/2013)... June 19, 2013 ... presents Innovative Drug Delivery Systems: ... Licensing Opportunities for Generic Pharmaceutical ... There are more than ... drugs approved all over the ...
(Date:6/19/2013)... Applied Rigaku Technologies, Inc. is pleased to publish ... sulfur in ultra-low sulfur diesel (ULSD) using the new ... . The analysis detailed in Rigaku Application Note 1272 ... International Standard specifies an energy dispersive X-ray fluorescence (EDXRF) ... automotive gasoline. , Regulations around the world have limited ...
(Date:6/19/2013)... CA (PRWEB) June 19, 2013 Adding ... Pipette.com is now stocked with Simport’s Dropette® and ... aimed at the customer doing basic biology, chemistry and ... and serology). , For over 35 years, Simport has ... plastic labware - products like the Simport Dropette®. Simport’s ...
Breaking Biology Technology:Community Mentor Wins Inaugural Bayer CropScience Bee Care Leadership Award 2Community Mentor Wins Inaugural Bayer CropScience Bee Care Leadership Award 3Community Mentor Wins Inaugural Bayer CropScience Bee Care Leadership Award 4Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies 2Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies 3Rigaku Publishes New Application Note for Analysis of ULSD Per ISO 13032 2Leading Pipette Distributor Pipette.com Now Stocks Transfer Pipettes: Simport’s Dropette and Heathrow Scientific Disposable Plastic Transfer Pipettes 2
... (Nasdaq: MNKD ), focused on discovering, developing and,commercializing ... present at the UBS Global Life Sciences Conference on ... Hyatt Hotel in New York, NY. Interested parties ... of the,presentation in the Investor Relations section of the ...
... Sept. 18 InterMune, Inc.,(Nasdaq: ITMN ) today ... other conditions, 3,000,000 shares of its common stock in ... underwriters,a 30-day option to purchase up to an additional ... All of the shares in the offering,will be sold ...
... Sept. 18 /PRNewswire-FirstCall/-- Biodel Inc. (Nasdaq:,BIOD) today ... program,at the 43rd Scientific Sessions of the ... VIAject(TM) Phase II meal study data ... entitled, "Pharmacokinetics and pharmacodynamics of,insulin VIAject(TM), insulin ...
Cached Biology Technology:InterMune Announces Proposed Public Offering of Common Stock 2Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting 2Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting 3
(Date:6/19/2013)... June 19, 2013 A decade-long JDRF-funded study ... Helmholtz Zentrum Mnchen, Germany, is providing a deeper ... risk of developing type 1 diabetes (T1D), highlighting ... for the disease. The study, "Seroconversion to Multiple ... in Children," was published today in The ...
(Date:6/19/2013)... , June 19, 2013  New York College ... the United States Patent and Trademark Office for detecting ... that reflect whether guards have been injured, attacked or ... extensive portfolio under the Intellectual Properties Agreements of New ... Pamintuan , President of New York ...
(Date:6/19/2013)... Elsevier, a world-leading provider of scientific, technical and ... the launch of a new open access journal, ... GeoResJ , Elsevier,s earth and planetary science journals portfolio ... aims to provide a forum for rapid publication of ... journal will be co-edited by six Executive Editors, each ...
Breaking Biology News(10 mins):New data on islet autoantibodies in young children defines early type 1 diabetes development 2New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 2New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 3New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 4
... a gene called p63 accelerates aging in mice. Similar versions ... Therefore, the p63 gene is likely to play a fundamental ... p63 gene works, we devised a system for eliminating it ... that these p63 deficient mice were aging prematurely," says Alea ...
... Genome Research Institute (NHGRI), one of the National Institutes ... Research Network will target 13 more organisms as part ... will expand biological knowledge and improve human health. , ... which is a federally chartered committee that advises NHGRI ...
... Skeletal muscles naturally repair themselves very efficiently after ... following damage from overuse during exercise, surgery or ... muscle repair slows noticeably, and in Duchenne Muscular ... functions can't cope with disease progression. , Researchers ...
Cached Biology News:Gene loss accelerates aging 2Possible treatment found for 'chemobrain' 2Possible treatment found for 'chemobrain' 3Possible treatment found for 'chemobrain' 4Possible treatment found for 'chemobrain' 5Muscle repair: Making a good system better, faster; implications for aging, disease 2Muscle repair: Making a good system better, faster; implications for aging, disease 3Muscle repair: Making a good system better, faster; implications for aging, disease 4
... Microarrays designed for genome-wide microRNA ... flexible and powerful Paraflo microfluidic on-chip ... as part of our comprehensive microRNA ... Content The Rice microRNA Microarray ...
... FP-6500 is the research-grade spectrofluorometer with a ... sensitivity S/N ratio 200 or greater for ... is especially designed to keep in mind ... as kinetics, stopped-flow, titration, or anisotropic measurements. ...
... genome-wide microRNA expression profiling and built ... microfluidic on-chip synthesis platform. These microarrays ... comprehensive microRNA Expression Profiling Service. ... microRNA Microarray contains all known fish ...
... designed for genome-wide microRNA expression profiling ... powerful Paraflo microfluidic on-chip synthesis platform. ... of our comprehensive microRNA Expression Profiling ... The Viruses microRNA Microarray contains all ...
Biology Products: